TL;DR: Curaleaf Holdings (OTCQX: CURLF), the largest US multi-state operator by store count, closes Saturday at a pivotal moment as DEA rescheduling hearings approach their final phase. The combination of a potential favorable ruling and ongoing 280E tax normalization creates a compounding earnings catalyst that disproportionately favors large-footprint operators. As investors position ahead of the July quarter, Curaleaf’s 17-plus state presence, recent operational discipline, and European medical exposure make it the most direct MSOS proxy for rescheduling upside.
Market Analysis
CURLF has spent much of 2026 consolidating below key resistance as the market digested the April announcement that medical cannabis would be moved to Schedule III — a ruling that confirmed the 280E deduction ban no longer applies to Schedule III sales. For Curaleaf, which generated more than $1.3 billion in revenue in fiscal 2025 across dispensary, wholesale, and cultivation channels, 280E normalization is not a rounding error. It is a structural shift that converts hundreds of millions in previously disallowed deductions into real pretax income.
As of Saturday’s close, CURLF is trading near levels that reflect the medical rescheduling but not yet a completed adult-use hearing process. That gap is where the forward-looking opportunity sits.
The MSOS ETF — the primary institutional proxy for US cannabis equities — extended its 2026 highs on Friday as the DEA hearing process entered its second day. CURLF, as one of the largest MSOS components, moves with the sector, but its relative positioning compared to single-state operators reflects a different risk/reward calculus: more states means more normalized revenue streams, deeper wholesale infrastructure, and the kind of cost-absorption capacity that allows genuine operating leverage when tax relief arrives.
Regulatory and Market Context
The DEA hearings currently underway are the second phase of the rescheduling process — this time examining the adult-use question. April’s medical reclassification was the more widely anticipated outcome; the adult-use hearings carry greater uncertainty and therefore greater option value for investors who believe the administrative record will support further liberalization.
For Curaleaf specifically, the regulatory timeline intersects with a restructuring story. The company spent 2024 and early 2025 divesting underperforming operations, exiting certain international markets, and concentrating capital on its highest-margin domestic dispensaries. The result is a leaner operation entering the rescheduling catalyst with stronger unit economics than it carried into the prior regulatory cycle.
European exposure adds a secondary layer. Curaleaf’s operations in Germany and the UK position it to benefit from the ongoing European medical cannabis build-out, which is largely independent of the US rescheduling timeline. As German legalization matures and UK medical access expands, the international segment — currently a drag on margins — could become accretive faster than US consensus models assume.
Sector Tone Heading Into July
Saturday’s trading session was light on volume, as expected for a summer weekend, but the week’s net performance in cannabis equities was positive. Peers reviewed earlier in the day — Trulieve, Verano, Canopy Growth, and IIP — each reflected their own version of the rescheduling optionality narrative. What distinguishes the Curaleaf setup is scale: no other OTCQX-listed cannabis operator controls as many operating dispensaries or has the wholesale infrastructure to service third-party retail at the volumes Curaleaf can.
If the DEA hearing record closes with a favorable adult-use recommendation — or even a neutral record that leaves the door open — Curaleaf’s operating leverage math improves substantially before a single new dispensary opens.
Conclusion: The Week Ahead
Investors tracking CURLF should watch two variables heading into the July 4 holiday-shortened trading week: any public commentary from DEA administrative law judges signaling the evidentiary record is closing, and Curaleaf’s own guidance communications around Q2 2026 results, which are expected in late July.
The end-of-day setup on Saturday is constructive. The rescheduling hearing process is closer to resolution than at any point in the past decade, 280E normalization is already partially priced in, and the largest US multi-state operator has used the past 18 months to right-size operations for a post-rescheduling environment. For traders and portfolio managers watching the cannabis stock tracker, CURLF remains the high-beta rescheduling proxy with the most credible fundamental underpinning heading into Q3 2026.
Sheeba M. is a cannabis market intelligence analyst covering US and international cannabis equities for Weedstock.